WuXi Biologics Achieves Eighth Consecutive CDMO Leadership Award
WuXi Biologics, a prominent global Contract Research, Development and Manufacturing Organization (CRDMO), has proudly announced its recent accolade of receiving the 2025 CDMO Leadership Awards in the "Biologics - Global" category. This recognition distinguishes the company not only for its commitment to advancing integrated technology platforms but also highlights its superior service across multiple categories, including "Best Scientific Expertise", "Best Seamless Delivery Across Phases", and "Best Innovative Approach to Technology and Process Execution." This achievement marks a significant milestone for WuXi Biologics, as it celebrates its eighth consecutive year of receiving this prestigious award.
Commitment to Advancing Biologics
WuXi Biologics is renowned for its dedication to transforming biologics discovery, development, and manufacturing processes. The company has successfully shorted the development timeline for monoclonal antibody projects, achieving remarkable efficiency from DNA to Investigational New Drug (IND) applications in just nine months. In fact, a recent project focused on autoimmune diseases was completed in an impressive six months. Through the utilization of single-use technology (SUT), WuXi Biologics has significantly scaled its manufacturing capabilities, enhancing its capacity from 4,000 to 16,000 liters across global facilities. The company boasts a noteworthy success rate of 99% from the years 2022 to 2024, showcasing its excellence in meeting client needs.
Quality Assurance and Regulatory Success
This major achievement is supported by WuXi Biologics' rigorous quality systems. The company has maintained a flawless 100% success rate in pre-approval inspections and has exceeded 40 global regulatory audits, including 22 assessments by the FDA and EMA. These accomplishments reflect WuXi Biologics' unwavering commitment to the highest standards in biologics manufacturing and ensure that clients can deliver safe and effective therapies to patients.
Leadership and Vision of the CEO
Dr. Chris Chen, the Chief Executive Officer of WuXi Biologics, expressed his gratitude, stating, "We are profoundly honored to receive the CDMO Leadership Award for the eighth consecutive year. This remarkable achievement signifies the trust our global partners place in us, and it is a testament to the relentless dedication of our entire team. Our mission remains clear: to empower our partners to bring life-saving treatments to market swiftly, ultimately benefiting patients around the globe."
About the CDMO Leadership Awards
The CDMO Leadership Awards are highly coveted accolades presented by Outsourced Pharma and Life Science Leader. For the 2025 awards, a total of 210 CDMOs were evaluated based on comprehensive third-party research, establishing the most esteemed names in the industry across categories such as Biologics, Cell & Gene Therapy, and Small Molecule API. This multi-faceted evaluation emphasizes the importance of quality and effectiveness in the biopharmaceutical landscape.
About WuXi Biologics
WuXi Biologics, with stock code 2269.HK, stands as a leader in the CRDMO sector, providing comprehensive, end-to-end solutions for biologics. It assists partners in discovering, developing, and manufacturing biologics – from concept to commercialization – with the ultimate goal of enhancing patient outcomes throughout the world.
Sustainability as a Core Value
The company is also committed to sustainability, viewing it as a foundational aspect of long-term business success. WuXi Biologics continuously innovates in green technologies, delivering advanced Green CRDMO solutions while adhering to high standards in Environmental, Social, and Governance (ESG) practices. This strong focus on sustainability not only fosters positive social and environmental change but also empowers every element of the value chain.
Frequently Asked Questions
What is the significance of the CDMO Leadership Award?
The CDMO Leadership Award recognizes outstanding contract development and manufacturing organizations, highlighting their service excellence in various categories.
How many years has WuXi Biologics won this award?
WuXi Biologics has won the CDMO Leadership Award for eight consecutive years, showcasing its consistent commitment to excellence.
What technologies does WuXi Biologics utilize?
WuXi Biologics employs integrated technology platforms, including single-use technology (SUT) to enhance biologics manufacturing processes.
How does WuXi Biologics assure quality?
The company has maintained a 100% success rate in pre-approval inspections and has successfully passed over 40 regulatory inspections worldwide.
What is WuXi Biologics' commitment to sustainability?
WuXi Biologics focuses on sustainable practices by innovating green technologies to provide environmentally friendly CRDMO solutions for its global partners.
